NCT06052852 is a Phase 1 clinical trial of BDC-3042 in Triple Negative Breast Cancer, sponsored by Bolt Biotherapeutics, Inc..

Who is sponsoring NCT06052852?

NCT06052852 is sponsored by Bolt Biotherapeutics, Inc..

What drugs are being tested in NCT06052852?

Interventions in NCT06052852: BDC-3042, Cemiplimab.

What condition does NCT06052852 study?

NCT06052852 studies Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma.

Is NCT06052852 still recruiting?

NCT06052852 is currently terminated. Last updated 17 November 2025.

Last reviewed 2025-11-17 · How we verify

NCT06052852

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Terminated Phase 1 Last updated 17 November 2025

What this trial tests

Phase 1 trial testing BDC-3042 in Triple Negative Breast Cancer in 17 participants. Terminated before completion.

Timeline

11 October 2023

Primary endpoint
1 August 2025

1 August 2025

Quick facts

Lead sponsor	Bolt Biotherapeutics, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	11 October 2023
Primary completion	1 August 2025
Estimated completion	1 August 2025
Sites	6 locations across United States

Drugs / interventions tested

BDC-3042 — full drug profile →
Cemiplimab (CEMIPLIMAB) — full drug profile →

Conditions studied

Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
Clear Cell Renal Cell Carcinoma — all drugs for Clear Cell Renal Cell Carcinoma →
Ovarian Cancer — all drugs for Ovarian Cancer →
Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Bolt Biotherapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Triple Negative Breast Cancer or Clear Cell Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical landscape of macrophage-reprogramming cancer immunotherapies.
Rannikko JH, Hollmén M. · · 2024 · cited 70× · PMID 38831013 · DOI 10.1038/s41416-024-02715-6
Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment.
Yang Y, Li H, Yang W, Shi Y. · · 2024 · cited 11× · PMID 39430759 · DOI 10.3389/fimmu.2024.1441667

Verify or expand the search:

Other recruiting trials for Triple Negative Breast Cancer

Currently open trials in the same condition.

NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting

Other Bolt Biotherapeutics, Inc. trials

Trials by the same sponsor.

NCT05954143 — Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer · Phase 2 · terminated
NCT04278144 — A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing So · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06052852 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bolt Biotherapeutics, Inc.
Last refreshed: 17 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06052852.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing